The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Guillain-Barre Syndrome

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Guillain-Barre Syndrome


Psychiatry related information on Guillain-Barre Syndrome


High impact information on Guillain-Barre Syndrome


Chemical compound and disease context of Guillain-Barre Syndrome


Biological context of Guillain-Barre Syndrome


Anatomical context of Guillain-Barre Syndrome


Gene context of Guillain-Barre Syndrome


Analytical, diagnostic and therapeutic context of Guillain-Barre Syndrome


  1. Parainfluenza virus type 3: isolation from CSF of a patient with Guillain-Barré syndrome. Román, G., Phillips, C.A., Poser, C.M. JAMA (1978) [Pubmed]
  2. The role of integrins in immune-mediated diseases of the nervous system. Archelos, J.J., Previtali, S.C., Hartung, H.P. Trends Neurosci. (1999) [Pubmed]
  3. Campylobacter infections, Guillain-Barré syndrome, and parenteral gangliosides. Callegaro, L., Jack, D.B., Samson, J.C. Lancet (1991) [Pubmed]
  4. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Kieseier, B.C., Clements, J.M., Pischel, H.B., Wells, G.M., Miller, K., Gearing, A.J., Hartung, H.P. Ann. Neurol. (1998) [Pubmed]
  5. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Hartung, H.P., Reiners, K., Schmidt, B., Stoll, G., Toyka, K.V. Ann. Neurol. (1991) [Pubmed]
  6. Antibody detection in Guillain-Barré syndrome. Svennerholm, L., Fredman, P. Ann. Neurol. (1990) [Pubmed]
  7. Acute post-gastric reduction surgery (APGARS) neuropathy. Chang, C.G., Adams-Huet, B., Provost, D.A. Obesity surgery : the official journal of the American Society for Bariatric Surgery and of the Obesity Surgery Society of Australia and New Zealand. (2004) [Pubmed]
  8. Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barré syndrome. Cochen, V., Arnulf, I., Demeret, S., Neulat, M.L., Gourlet, V., Drouot, X., Moutereau, S., Derenne, J.P., Similowski, T., Willer, J.C., Pierrot-Deseiligny, C., Bolgert, F. Brain (2005) [Pubmed]
  9. Clitoral pain: the great unexplored pain in women. Gordon, A.S. Journal of sex & marital therapy. (2002) [Pubmed]
  10. Guillain-Barré syndrome and serum activities of gamma-glutamyltransferase and glutamic-pyruvic transaminase. Kornhuber, J., Kornhuber, A.W., Kaiserauer, C.H., Wanner, W.E. European archives of psychiatry and neurological sciences. (1988) [Pubmed]
  11. Multiple sclerosis, Guillain-Barré syndrome and myelin basic protein-specific cellular antibody. Johnson, A.B., Dal Canto, M.C. Nature (1976) [Pubmed]
  12. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. Yuki, N., Taki, T., Inagaki, F., Kasama, T., Takahashi, M., Saito, K., Handa, S., Miyatake, T. J. Exp. Med. (1993) [Pubmed]
  13. A 71-year-old male with 4 decades of symptoms referable to both central and peripheral nervous system. Quan, D., Kleinschmidt-DeMasters, B.K. Brain Pathol. (2005) [Pubmed]
  14. N-glycolylneuraminic acid-containing GM1 is a new molecule for serum antibody in Guillain-Barré syndrome. Odaka, M., Yuki, N., Yoshino, H., Kasama, T., Handa, S., Irie, F., Hirabayashi, Y., Suzuki, A., Hirata, K. Ann. Neurol. (1998) [Pubmed]
  15. Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. Ma, J.J., Nishimura, M., Mine, H., Kuroki, S., Nukina, M., Ohta, M., Saji, H., Obayashi, H., Kawakami, H., Saida, T., Uchiyama, T. Ann. Neurol. (1998) [Pubmed]
  16. Ineffectiveness of high-dose intravenous methylprednisolone in Guillain-Barré syndrome. Hughes, R.A. Lancet (1991) [Pubmed]
  17. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Rees, J.H., Gregson, N.A., Hughes, R.A. Ann. Neurol. (1995) [Pubmed]
  18. Capsaicin for the treatment of pain in Guillain-Barré syndrome. Morgenlander, J.C., Hurwitz, B.J., Massey, E.W. Ann. Neurol. (1990) [Pubmed]
  19. Inappropriate secretion of antidiuretic hormone associated with Guillain-Barré syndrome. Hochman, M.S., Kobetz, S.A., Handwerker, J.V. Ann. Neurol. (1982) [Pubmed]
  20. National surveillance for Guillain-Barré syndrome: January 1978-March 1979. Hurwitz, E.S., Holman, R.C., Nelson, D.B., Schonberger, L.B. Neurology (1983) [Pubmed]
  21. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome. Bowes, T., Wagner, E.R., Boffey, J., Nicholl, D., Cochrane, L., Benboubetra, M., Conner, J., Furukawa, K., Furukawa, K., Willison, H.J. Infect. Immun. (2002) [Pubmed]
  22. Restriction fragment length polymorphism analysis and random amplified polymorphic DNA analysis of Campylobacter jejuni strains isolated from patients with Guillain-Barré syndrome. Fujimoto, S., Allos, B.M., Misawa, N., Patton, C.M., Blaser, M.J. J. Infect. Dis. (1997) [Pubmed]
  23. Apolipoprotein E genotypes and clinical outcome in Guillain-Barré syndrome. Pritchard, J., Hughes, R.A., Rees, J.H., Willison, H.J., Nicoll, J.A. J. Neurol. Neurosurg. Psychiatr. (2003) [Pubmed]
  24. Macrophage procoagulant activity as a measure of cell-mediated immunity to P2 protein of peripheral nerves in the Guillain-Barré syndrome. Geczy, C., Raper, R., Roberts, I.M., Meyer, P., Bernard, C.C. J. Neuroimmunol. (1985) [Pubmed]
  25. Immune-mediated demyelination. Hartung, H.P. Ann. Neurol. (1993) [Pubmed]
  26. Isolation of P2 protein--reactive T-cell lines from human blood. Burns, J., Krasner, L.J., Rostami, A., Pleasure, D. Ann. Neurol. (1986) [Pubmed]
  27. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Hirota, N., Kaji, R., Bostock, H., Shindo, K., Kawasaki, T., Mizutani, K., Oka, N., Kohara, N., Saida, T., Kimura, J. Brain (1997) [Pubmed]
  28. Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome. Hemachudha, T., Griffin, D.E., Chen, W.W., Johnson, R.T. Neurology (1988) [Pubmed]
  29. Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases. Cammer, W., Brosnan, C.F., Bloom, B.R., Norton, W.T. J. Neurochem. (1981) [Pubmed]
  30. Induction of experimental autoimmune neuritis with peripheral myelin protein-22. Gabriel, C.M., Hughes, R.A., Moore, S.E., Smith, K.J., Walsh, F.S. Brain (1998) [Pubmed]
  31. Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome. Créange, A., Sharshar, T., Planchenault, T., Christov, C., Poron, F., Raphaël, J.C., Gherardi, R.K. Neurology (1999) [Pubmed]
  32. PML bodies in reactive sensory ganglion neurons of the Guillain-Barré syndrome. Villagrá, N.T., Berciano, J., Altable, M., Navascués, J., Casafont, I., Lafarga, M., Berciano, M.T. Neurobiol. Dis. (2004) [Pubmed]
  33. Circulating tumor necrosis factor (TNF)-alpha and soluble TNF-alpha receptors in patients with Guillain-Barré syndrome. Créange, A., Bélec, L., Clair, B., Raphaël, J.C., Gherardi, R.K. J. Neuroimmunol. (1996) [Pubmed]
  34. Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function. Créange, A., Bélec, L., Clair, B., Degos, J.D., Raphaël, J.C., Gherardi, R.K. J. Neurol. Neurosurg. Psychiatr. (1998) [Pubmed]
  35. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Yuki, N., Yamada, M., Koga, M., Odaka, M., Susuki, K., Tagawa, Y., Ueda, S., Kasama, T., Ohnishi, A., Hayashi, S., Takahashi, H., Kamijo, M., Hirata, K. Ann. Neurol. (2001) [Pubmed]
  36. Mycoplasma antibody in Guillain-Barré syndrome and other neurological disorders. Goldschmidt, B., Menonna, J., Fortunato, J., Dowling, P., Cook, S. Ann. Neurol. (1980) [Pubmed]
  37. Plasma exchange and prednisone in Guillain-Barré syndrome: a controlled randomized trial. Mendell, J.R., Kissel, J.T., Kennedy, M.S., Sahenk, Z., Grinvalsky, H.T., Pittman, G.L., Kyler, R.S., Roelofs, R.I., Whitaker, J.N., Bertorini, T.E. Neurology (1985) [Pubmed]
  38. High-titer selective serum anti-beta-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Connolly, A.M., Pestronk, A., Trotter, J.L., Feldman, E.L., Cornblath, D.R., Olney, R.K. Neurology (1993) [Pubmed]
  39. Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease. Dau, P.C. J. Neuroimmunol. (1990) [Pubmed]
WikiGenes - Universities